Bayer shares have hit a rough patch, shedding value for five consecutive trading sessions, yet the underlying picture is far from bleak. The stock closed Friday at €46.01, marking a weekly decline of 4.48% — a pullback that stands in sharp contrast to the stock’s broader trajectory. Since the start of the year, Bayer has still gained 24.32%, and over the past twelve months, the rally has been even more pronounced at 58.74%.
The recent weakness appears to be a consolidation phase rather than a reversal of fortune. The shares now trade 14.57% below their 52-week high set on July 3, and the Relative Strength Index sits at a neutral 49.6, suggesting the stock is neither overbought nor oversold. The annualized 30-day volatility of 63.31% underscores the persistent turbulence that has become a hallmark of Bayer’s equity story.
That volatility has deep roots in the legal battles surrounding Roundup, the glyphosate-based herbicide that has haunted the company for years. But on June 25, the U.S. Supreme Court delivered a decisive victory for Bayer, ruling 7-2 that the company cannot be sued under state law for failing to warn about cancer risks associated with the product. The decision effectively removes one of the most potent legal weapons plaintiffs had wielded, reshaping the risk calculus that investors have applied to the stock for years.
Should investors sell immediately? Or is it worth buying Bayer?
The market has already absorbed this legal relief. The 58.74% twelve-month gain reflects the shift in sentiment, even if the stock has cooled from its recent peak. The ruling does not eliminate all litigation — individual cases and potential future claims remain — but it strips away a central avenue for attack, and investors will be watching upcoming earnings reports for signs that this translates into lower provisions or a calmer news flow.
JPMorgan remains firmly in the bull camp. Analyst Richard Vosser has reiterated an “Overweight” rating and a €50 price target, a level that implies meaningful upside from current prices. His conviction is grounded in expectations that Bayer’s revenue and adjusted operating profit forecasts align with market consensus, and that the company will reaffirm its full-year guidance when it reports second-quarter results on August 4. Vosser had already anticipated solid Q2 numbers ahead of the half-year figures.
The convergence of a landmark legal win and an imminent earnings report creates a pivotal moment for Bayer. The stock’s five-day losing streak may simply be a pause before the next leg — or a sign that the market needs fresh catalysts to push shares higher. With the Supreme Court having narrowed the legal battlefield and JPMorgan holding firm on its target, the August 4 earnings release now carries outsized weight. If Bayer confirms its annual targets as expected, the current consolidation could give way to renewed momentum.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 26 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 26.
Bayer: Buy or sell? Read more here...
